aidsmap news story
Merck’s investigational once-monthly PrEP pill could be manufactured and sold profitably for around $3 per person per year, making it the cheapest HIV prevention drug ever brought to market, the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro heard. But the licensing deal announced by the company days earlier leaves out most of Latin America, including countries hosting the drug’s own phase III trials.
MK-8527, now known as alimatravir, belongs to a new class of drugs called nucleoside reverse transcriptase translocation inhibitors. It is taken as a single tablet once a month at a dose of 11 mg, compared to 500 mg a day for oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).
Read the full news story here.
View all aidsmap reports from AIDS 2026
Source : aidsmap
Related HIV and Co-Infections News
-
[AIDS 2026] aidsmap: Nearly 200,000 lenacapavir shots given across Africa, but supply issues pose challenges
-
[AIDS 2026] Countries in Latin America and the Caribbean helped build the future of HIV prevention. But will they be able to benefit from it?
-
[AIDS 2026] [Report] UNAIDS: Global HIV response falters as reemergence looms
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.